Merck & Company (MRK) 60.56 $MRK
OTC Drug Market in India 2014
M2 - 1 hr 37 mins ago
Research and Markets (http://www.researchandmarkets.com/research/2nxxm7/otc_drug_market) has announced the addition of the "OTC Drug Market in India 2014 " report to their offering. This latest market research report titled OTC Drug Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing self-medicated patient population, growing confidence in OTC drugs, and change of prescription drugs to OTC drugs are the key drivers of this market. The various segments of OTC drugs such as Vitamins & Minerals, Gastrointestinal, and Cough Cold & Allergy etc. are the major reasons for the popularity of the OTC drug market. Growing number of self-treatment patient base and their confidence in the OTC drugs is helping the Indian market to grow. Prescription drugs, after becoming OTC, present a huge opportunity for growth. OTC drugs increase the availability of different types of drugs intended for self-medication among patients, which helps in the growth of the market. The increasing disposable income of people is also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies. Another challenge is the penetration of OTC drugs in rural areas which is very low. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well. Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Value Chain - Drivers & Challenges - Government Initiatives - Regulations - Competitive Landscape - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies - Amrutanjan Healthcare Ltd. - Cipla Ltd. - Dr. Reddy's Laboratories Ltd. - GlaxoSmithKline Pharmaceuticals Ltd. - Lupin Ltd. - Novartis India Ltd. - Pfizer Ltd. - P&G - Ranbaxy Laboratories Ltd. - Merck Ltd Sun Pharmaceutical Industries Ltd.. For more information visit http://www.researchandmarkets.com/research/2n...rug_market
Broccolini and Magil Laurentian Announce the Acquisition of the Former Merck Canada Complex in Kirkland, Quebec
PR Newswire Europe - Tue Sep 09, 5:10PM CDT
KIRKLAND, Quebec, September 9, 2014 /PRNewswire/ --
TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:00PM CDT
TESARO, Inc. (TSRO) submitted a new drug application for its pipeline candidate, oral rolapitant, to the FDA.
Broccolini and Magil Laurentian announce the acquisition of the former Merck Canada complex in Kirkland, Quebec
PR Newswire - Tue Sep 09, 2:08PM CDT
Broccolini Limited Partnership No. 2 and Magil Laurentian Realty Investments announced today that they have closed on the acquisition of the former Merck Canada complex along the TransCanada Highway in Kirkland, Quebec. Broccolini and Magil Laurentian have joined forces to develop this world-class 50-acre business and mixed-use campus which was renamed "Quartier Évolution". The partnership between Broccolini and Magil Laurentian brings together a qualified team of professionals in construction, real estate development and property management, in order to fully meet the needs of future tenants.
Watch for Shares of Merck (MRK) to Approach Support at $60.57
Comtex SmarTrend(R) - Tue Sep 09, 12:26PM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $61.07 today and has reached the first level of support at $60.81. Analysts will be watching for a cross of the next downside pivot targets of $60.57 and $60.07.
Cardiovascular Pharmaceuticals Market in India 2014
M2 - Tue Sep 09, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rgkkvk/cardiovascular) has announced the addition of the "Cardiovascular Pharmaceuticals Market in India 2014" report to their offering. This market research report titled Cardiovascular Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing patient population, patent expiry of blockbuster drugs, and introduction of newer and better drugs are the key drivers of this market. Cardiovascular pharmaceuticals is one of the leading therapeutic segments of the overall pharma industry and cardiovascular diseases (CVDs) are the top causes of deaths worldwide Growing incidences of cardiovascular diseases is helping the Indian market to grow and large pharmaceutical companies are trying to launch new patented blockbuster drugs to tackle the situation. Patented blockbuster drugs, after becoming generic, present a huge opportunity for growth. Generic drugs increase the affordability among patients, which helps in the growth of the market. The increasing disposable income of people are also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies and competition from complementary and alternative medicines. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Value Chain - Drivers & Challenges - Government Initiatives - Competitive Landscape - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies: - AstraZeneca Pharma India Ltd. - Sanofi India Ltd. - Cipla Ltd. - Dr. Reddy's Laboratories Ltd. - GlaxoSmithKline Pharmaceuticals Ltd. - Lupin Ltd. - Merck Ltd. - Novartis India Ltd. - Pfizer Ltd. - Ranbaxy Laboratories Ltd. - Sun Pharmaceutical Industries Ltd. - Torrent Pharmaceutical Ltd. Private Companies: - Bristol-Myers Squibb India Pvt. Ltd. - Cadila Pharmaceuticals Ltd. - Intas Pharmaceuticals Ltd. - USV Ltd. For more information visit http://www.researchandmarkets.com/research/rg...iovascular
Four New Partner Organizations Join Optum Labs Research Collaborative
Business Wire - Tue Sep 09, 7:01AM CDT
Optum Labs, the collaborative research and innovation center co-founded by Optum and Mayo Clinic, announced the addition of four new partners committed to improving the quality and value of patient care.
Merck kicks off its second year fight against diabetes by adopting e-learning solutions to build healthcare capacity in Africa
M2 - Tue Sep 09, 6:52AM CDT
- Merck is reaching to health professionals in rural areas by providing SMS and e-learning platform for diabetes
Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GSK, J&J Merck & Pfizer
M2 - Tue Sep 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5tdjb4/global_infectious) has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. The analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43% over the period 2013-2018. Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. One of the emerging trends in this market is the emergence of Interferon-free regimens. Various all-oral, IFN-free regimens are under development and are expected to attain higher sustained virologic response and cause fewer side effects than the currently approved therapies. According to the report, the launch of Direct-acting Antivirals is one of the major drivers for the Global Infectious Disease Treatment market. DAAs are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN and increase the efficacy of treatment and decrease the duration of therapy and this leads to increased preference for this treatment among patients. Further, the report states that a generic erosion of marketed drugs is one of the major challenges faced by the market. A loss of patent protection and market exclusivity generally triggers the entry of low-cost alternatives for drugs, which, in turn, decreases the sales of innovator-approved drugs. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include: - Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials) - Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals) - Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs) - Antiparasitic drugs Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck - Pfizer For more information visit http://www.researchandmarkets.com/research/5t...infectious
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO
Business Wire - Mon Sep 08, 7:15PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that after a long and thoughtful strategic planning process to recruit a new President and Chief Operating Officer (COO), Acucela has appointed Brian O'Callaghan, who currently sits on Acucela's Board of Directors, to the newly created position, effective immediately. Ryo Kubota, MD, PhD, who is also Acucela's Founder, will remain as Acucela's Chairman of the Board (Chairman) and Chief Executive Officer (CEO). In a separate development, Acucela's Chief Financial Officer (CFO), David Lowrance, will be leaving the Company for family reasons. As a result of Mr. Lowrance's departure, Mr. O'Callaghan will also assume the role of Interim CFO. An active search is underway to appoint a new CFO. Mr. O'Callaghan brings to Acucela over 25 years of leadership experience in the biotechnology and pharmaceutical industries, including senior positions at Bayer, Merck, Novartis, NPS Pharmaceuticals, Pfizer, and Sangart. He will report directly into Dr. Kubota.
Merck to Participate at the Morgan Stanley Global Healthcare Conference
Business Wire - Mon Sep 08, 4:00PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer; Adam H. Schechter, executive vice president and president, Global Human Health; and Dr. Roy Baynes, senior vice president, Clinical Development, Merck Research Laboratories, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York on Sept. 9, 2014 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to live audio presentation of the webcasts at http://www.merck.com/investors/events-and-pre.../home.html.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
One Put, One Call Option To Know About for Merck & Co., Inc (MRK)
StockOptionsChannel.com - Mon Sep 08, 11:18AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the...
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
The Surprising 7 States Where Melanoma Most Often Occurs
Sean Williams, The Motley Fool - Motley Fool - Sun Sep 07, 10:52AM CDT
Source: National Cancer Institute via Wikimedia Commons. Cancer is a scary disease regardless of its type, but for those suffering with melanoma, a malignant form of skin cancer, it's been an especially frightening couple of decades. According to...
7 States Where Diabetes Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 06, 12:14PM CDT
Diabetes: It's one of the most widespread chronic diseases in the United States, yet is also one of the most ignored and underdiagnosed. According to the latest statistics from the Centers for Disease Control and Prevention in its National...
Membrane Technology Market in Pharmaceutical, Biopharma and Life Sciences by Transparency Market Research
PRWeb - Fri Sep 05, 1:01PM CDT
The constantly growing global marketplace offers continually enhancing products, while maintaining cost-reduction is paramount. Hence, the sanitary line of membrane separation systems and technologies plays a vital role in multifarious industries including industrial biotechnology and pharmaceutical industries. Brief Introduction Membrane processes are commonly used in industrial applications as they easily replace distillation and evaporation at improved economics. Membrane separation technologies such as ultrafiltration, reverse osmosis, and microfiltration are often used to purify and concentrate both small and large molecules in a given application. Membrane technology has experienced significant development in the last couple of decades. And to this day, the market continues to grow stronger due to certain factors such as environmental regulations, challenges related to water supply and sanitation, advancement of material science and process technologies, and exploration of new applications - all of which are rapidly increasing in emerging regions. Browse Full Report Membrane Technology Market Report: http://www.transparencymarketresearch.com/mem...arket.html The Need of Membrane Systems The constantly growing populations across the world and diminishing fresh water sources due to environmental degradation and drought sources that have caused shortages of water have led the world into a huge demand for usable and clean water. Seemingly, such aspects have given rise to advances in membrane filtration and separation technologies from biotechnology development to purification of water supply. According to the global statistics, the past three decades has shown a rise in the desalination systems that have specifically emerged as effective solutions for changing contaminated water or other liquids into potable or usable products for domestic and commercial use. Worldwide experts estimate that technical advancements in membrane technology coupled with improvements in the membrane-based reverse osmosis RO systems have resulted in an 80% cost-reduction for desalinated water, and hence the need and growth of such systems is increasing year-on-year basis. Membrane Technology in Pharmaceuticals Applications Most of the times there are different membrane technologies leveraged in the field of pharmaceutical Research & Development. Some of them include phosphatidylcholine-immobilized artificial membrane used in vitro pharmacodynamic study for drug absorption profiling and hollow fiber membrane. Also, there is structural and screening characterization of reactive metabolites that helps to reduce attrition rates in drug development. This has increasingly become a fundamental part of the ADMET-guided lead optimization process in drug discovery. The need for detecting reactive metabolites is highly required in the pharmaceutical industry. Moreover, its use is also seen in the biomedical industry where synthetic polymer membranes are used in a wide range of applications including blood oxygenators, hemodialysis, and controlled release of therapeutics. Get report sample PDF copy from here: http://www.transparencymarketresearch.com/sam...ep_id=1848 Global Market Growth of the Membrane Technology Market Due to increasing research and development, and advancements in production in biopharmaceutical, life sciences, and pharmaceutical sectors, the membrane technology market is witnessing remarkable growth across different verticals. The global membrane technology market is estimated at USD 6,461.3 million in 2013 and is further expected to grow at a CAGR of 9.1% in the forecast period of 2014 to 2019, and reach an estimated value of USD 10,886 million in 2019. The major players in this global market are GE Healthcare and 3M Healthcare, along with some other players that include Sartorius, Merck Millipore, Koch Membrane System, Novasep, and more. Additionally, some of the major countries active in the advancements of membrane technology market are seen in regions such as North America, Asia Pacific, Europe, and Rest of the World (RoW).
Dow Today: Merck (MRK) Higher
at The Street - Fri Sep 05, 12:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting an 80-cent gain (+1.3%) bringing the stock to $60.88.
Merck (MRK) Breaks Through Resistance at $60.75
Comtex SmarTrend(R) - Fri Sep 05, 11:41AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $60.33 today and have reached the first resistance level of $60.75. Analysts will be watching for a cross of the next upside pivot targets of $61.41 and $62.49.
OTC Drug Market in India 2014
M2 - 1 hr 37 mins ago
Research and Markets (http://www.researchandmarkets.com/research/2nxxm7/otc_drug_market) has announced the addition of the "OTC Drug Market in India 2014 " report to their offering. This latest market research report titled OTC Drug Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing self-medicated patient population, growing confidence in OTC drugs, and change of prescription drugs to OTC drugs are the key drivers of this market. The various segments of OTC drugs such as Vitamins & Minerals, Gastrointestinal, and Cough Cold & Allergy etc. are the major reasons for the popularity of the OTC drug market. Growing number of self-treatment patient base and their confidence in the OTC drugs is helping the Indian market to grow. Prescription drugs, after becoming OTC, present a huge opportunity for growth. OTC drugs increase the availability of different types of drugs intended for self-medication among patients, which helps in the growth of the market. The increasing disposable income of people is also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies. Another challenge is the penetration of OTC drugs in rural areas which is very low. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well. Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Value Chain - Drivers & Challenges - Government Initiatives - Regulations - Competitive Landscape - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies - Amrutanjan Healthcare Ltd. - Cipla Ltd. - Dr. Reddy's Laboratories Ltd. - GlaxoSmithKline Pharmaceuticals Ltd. - Lupin Ltd. - Novartis India Ltd. - Pfizer Ltd. - P&G - Ranbaxy Laboratories Ltd. - Merck Ltd Sun Pharmaceutical Industries Ltd.. For more information visit http://www.researchandmarkets.com/research/2n...rug_market
Broccolini and Magil Laurentian Announce the Acquisition of the Former Merck Canada Complex in Kirkland, Quebec
PR Newswire Europe - Tue Sep 09, 5:10PM CDT
KIRKLAND, Quebec, September 9, 2014 /PRNewswire/ --
TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:00PM CDT
TESARO, Inc. (TSRO) submitted a new drug application for its pipeline candidate, oral rolapitant, to the FDA.
Broccolini and Magil Laurentian announce the acquisition of the former Merck Canada complex in Kirkland, Quebec
PR Newswire - Tue Sep 09, 2:08PM CDT
Broccolini Limited Partnership No. 2 and Magil Laurentian Realty Investments announced today that they have closed on the acquisition of the former Merck Canada complex along the TransCanada Highway in Kirkland, Quebec. Broccolini and Magil Laurentian have joined forces to develop this world-class 50-acre business and mixed-use campus which was renamed "Quartier Évolution". The partnership between Broccolini and Magil Laurentian brings together a qualified team of professionals in construction, real estate development and property management, in order to fully meet the needs of future tenants.
Watch for Shares of Merck (MRK) to Approach Support at $60.57
Comtex SmarTrend(R) - Tue Sep 09, 12:26PM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $61.07 today and has reached the first level of support at $60.81. Analysts will be watching for a cross of the next downside pivot targets of $60.57 and $60.07.
Cardiovascular Pharmaceuticals Market in India 2014
M2 - Tue Sep 09, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rgkkvk/cardiovascular) has announced the addition of the "Cardiovascular Pharmaceuticals Market in India 2014" report to their offering. This market research report titled Cardiovascular Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing patient population, patent expiry of blockbuster drugs, and introduction of newer and better drugs are the key drivers of this market. Cardiovascular pharmaceuticals is one of the leading therapeutic segments of the overall pharma industry and cardiovascular diseases (CVDs) are the top causes of deaths worldwide Growing incidences of cardiovascular diseases is helping the Indian market to grow and large pharmaceutical companies are trying to launch new patented blockbuster drugs to tackle the situation. Patented blockbuster drugs, after becoming generic, present a huge opportunity for growth. Generic drugs increase the affordability among patients, which helps in the growth of the market. The increasing disposable income of people are also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies and competition from complementary and alternative medicines. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Value Chain - Drivers & Challenges - Government Initiatives - Competitive Landscape - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies: - AstraZeneca Pharma India Ltd. - Sanofi India Ltd. - Cipla Ltd. - Dr. Reddy's Laboratories Ltd. - GlaxoSmithKline Pharmaceuticals Ltd. - Lupin Ltd. - Merck Ltd. - Novartis India Ltd. - Pfizer Ltd. - Ranbaxy Laboratories Ltd. - Sun Pharmaceutical Industries Ltd. - Torrent Pharmaceutical Ltd. Private Companies: - Bristol-Myers Squibb India Pvt. Ltd. - Cadila Pharmaceuticals Ltd. - Intas Pharmaceuticals Ltd. - USV Ltd. For more information visit http://www.researchandmarkets.com/research/rg...iovascular
Four New Partner Organizations Join Optum Labs Research Collaborative
Business Wire - Tue Sep 09, 7:01AM CDT
Optum Labs, the collaborative research and innovation center co-founded by Optum and Mayo Clinic, announced the addition of four new partners committed to improving the quality and value of patient care.
Merck kicks off its second year fight against diabetes by adopting e-learning solutions to build healthcare capacity in Africa
M2 - Tue Sep 09, 6:52AM CDT
- Merck is reaching to health professionals in rural areas by providing SMS and e-learning platform for diabetes
Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GSK, J&J Merck & Pfizer
M2 - Tue Sep 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5tdjb4/global_infectious) has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. The analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43% over the period 2013-2018. Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. One of the emerging trends in this market is the emergence of Interferon-free regimens. Various all-oral, IFN-free regimens are under development and are expected to attain higher sustained virologic response and cause fewer side effects than the currently approved therapies. According to the report, the launch of Direct-acting Antivirals is one of the major drivers for the Global Infectious Disease Treatment market. DAAs are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN and increase the efficacy of treatment and decrease the duration of therapy and this leads to increased preference for this treatment among patients. Further, the report states that a generic erosion of marketed drugs is one of the major challenges faced by the market. A loss of patent protection and market exclusivity generally triggers the entry of low-cost alternatives for drugs, which, in turn, decreases the sales of innovator-approved drugs. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include: - Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials) - Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals) - Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs) - Antiparasitic drugs Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck - Pfizer For more information visit http://www.researchandmarkets.com/research/5t...infectious
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO
Business Wire - Mon Sep 08, 7:15PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that after a long and thoughtful strategic planning process to recruit a new President and Chief Operating Officer (COO), Acucela has appointed Brian O'Callaghan, who currently sits on Acucela's Board of Directors, to the newly created position, effective immediately. Ryo Kubota, MD, PhD, who is also Acucela's Founder, will remain as Acucela's Chairman of the Board (Chairman) and Chief Executive Officer (CEO). In a separate development, Acucela's Chief Financial Officer (CFO), David Lowrance, will be leaving the Company for family reasons. As a result of Mr. Lowrance's departure, Mr. O'Callaghan will also assume the role of Interim CFO. An active search is underway to appoint a new CFO. Mr. O'Callaghan brings to Acucela over 25 years of leadership experience in the biotechnology and pharmaceutical industries, including senior positions at Bayer, Merck, Novartis, NPS Pharmaceuticals, Pfizer, and Sangart. He will report directly into Dr. Kubota.
Merck to Participate at the Morgan Stanley Global Healthcare Conference
Business Wire - Mon Sep 08, 4:00PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer; Adam H. Schechter, executive vice president and president, Global Human Health; and Dr. Roy Baynes, senior vice president, Clinical Development, Merck Research Laboratories, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York on Sept. 9, 2014 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to live audio presentation of the webcasts at http://www.merck.com/investors/events-and-pre.../home.html.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
One Put, One Call Option To Know About for Merck & Co., Inc (MRK)
StockOptionsChannel.com - Mon Sep 08, 11:18AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the...
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
The Surprising 7 States Where Melanoma Most Often Occurs
Sean Williams, The Motley Fool - Motley Fool - Sun Sep 07, 10:52AM CDT
Source: National Cancer Institute via Wikimedia Commons. Cancer is a scary disease regardless of its type, but for those suffering with melanoma, a malignant form of skin cancer, it's been an especially frightening couple of decades. According to...
7 States Where Diabetes Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 06, 12:14PM CDT
Diabetes: It's one of the most widespread chronic diseases in the United States, yet is also one of the most ignored and underdiagnosed. According to the latest statistics from the Centers for Disease Control and Prevention in its National...
Membrane Technology Market in Pharmaceutical, Biopharma and Life Sciences by Transparency Market Research
PRWeb - Fri Sep 05, 1:01PM CDT
The constantly growing global marketplace offers continually enhancing products, while maintaining cost-reduction is paramount. Hence, the sanitary line of membrane separation systems and technologies plays a vital role in multifarious industries including industrial biotechnology and pharmaceutical industries. Brief Introduction Membrane processes are commonly used in industrial applications as they easily replace distillation and evaporation at improved economics. Membrane separation technologies such as ultrafiltration, reverse osmosis, and microfiltration are often used to purify and concentrate both small and large molecules in a given application. Membrane technology has experienced significant development in the last couple of decades. And to this day, the market continues to grow stronger due to certain factors such as environmental regulations, challenges related to water supply and sanitation, advancement of material science and process technologies, and exploration of new applications - all of which are rapidly increasing in emerging regions. Browse Full Report Membrane Technology Market Report: http://www.transparencymarketresearch.com/mem...arket.html The Need of Membrane Systems The constantly growing populations across the world and diminishing fresh water sources due to environmental degradation and drought sources that have caused shortages of water have led the world into a huge demand for usable and clean water. Seemingly, such aspects have given rise to advances in membrane filtration and separation technologies from biotechnology development to purification of water supply. According to the global statistics, the past three decades has shown a rise in the desalination systems that have specifically emerged as effective solutions for changing contaminated water or other liquids into potable or usable products for domestic and commercial use. Worldwide experts estimate that technical advancements in membrane technology coupled with improvements in the membrane-based reverse osmosis RO systems have resulted in an 80% cost-reduction for desalinated water, and hence the need and growth of such systems is increasing year-on-year basis. Membrane Technology in Pharmaceuticals Applications Most of the times there are different membrane technologies leveraged in the field of pharmaceutical Research & Development. Some of them include phosphatidylcholine-immobilized artificial membrane used in vitro pharmacodynamic study for drug absorption profiling and hollow fiber membrane. Also, there is structural and screening characterization of reactive metabolites that helps to reduce attrition rates in drug development. This has increasingly become a fundamental part of the ADMET-guided lead optimization process in drug discovery. The need for detecting reactive metabolites is highly required in the pharmaceutical industry. Moreover, its use is also seen in the biomedical industry where synthetic polymer membranes are used in a wide range of applications including blood oxygenators, hemodialysis, and controlled release of therapeutics. Get report sample PDF copy from here: http://www.transparencymarketresearch.com/sam...ep_id=1848 Global Market Growth of the Membrane Technology Market Due to increasing research and development, and advancements in production in biopharmaceutical, life sciences, and pharmaceutical sectors, the membrane technology market is witnessing remarkable growth across different verticals. The global membrane technology market is estimated at USD 6,461.3 million in 2013 and is further expected to grow at a CAGR of 9.1% in the forecast period of 2014 to 2019, and reach an estimated value of USD 10,886 million in 2019. The major players in this global market are GE Healthcare and 3M Healthcare, along with some other players that include Sartorius, Merck Millipore, Koch Membrane System, Novasep, and more. Additionally, some of the major countries active in the advancements of membrane technology market are seen in regions such as North America, Asia Pacific, Europe, and Rest of the World (RoW).
Dow Today: Merck (MRK) Higher
at The Street - Fri Sep 05, 12:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting an 80-cent gain (+1.3%) bringing the stock to $60.88.
Merck (MRK) Breaks Through Resistance at $60.75
Comtex SmarTrend(R) - Fri Sep 05, 11:41AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $60.33 today and have reached the first resistance level of $60.75. Analysts will be watching for a cross of the next upside pivot targets of $61.41 and $62.49.
